A reference set of health utilities for long-term survivors of prostate cancer: Population-based data from Ontario, Canada

Quality of Life Research

Volumn 22, Issue 10, 2013, Pages 2951-2962

  Krahn, Murray D ^a,b,c,d,e   Bremner, Karen E ^a,d   Alibhai, Shabbir M H ^a,b   Ni, Andy ^b,f   Tomlinson, George ^a,b   Laporte, Audrey ^a,b   Naglie, Gary ^a,b,d,g  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f University of North Carolina at Chapel Hill   (United States)

^g TORONTO REHABILITATION INSTITUTE   (Canada)

Author keywords

Prostatic neoplasms; Quality of life; Utility measures

Indexed keywords

ADULT; AGED; ARTICLE; CANADA; COST BENEFIT ANALYSIS; HEALTH SERVICE; HEALTH STATUS; HEALTH SURVEY; HUMAN; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSTATE TUMOR; PSYCHOLOGICAL ASPECT; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; REGRESSION ANALYSIS; SOCIOECONOMICS; SURVIVOR; UTILIZATION REVIEW; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CANADA; COST-BENEFIT ANALYSIS; HEALTH SERVICES; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; ONTARIO; PATIENT SATISFACTION; POPULATION SURVEILLANCE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; REGRESSION ANALYSIS; SOCIOECONOMIC FACTORS; SURVIVORS;

EID: 84892833481     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-013-0401-1     Document Type: Article

References (52)

1. Bray, F., Jemal, A., Grey, N., Ferlay, J., & Forman, D. (2012). Global cancer transitions according to the human development index (2008-2030): A population-based study. The Lancet Oncology,13, 790-801.
2. Soerjomataram, I., Lortet-Tieulent, J., Parkin, D. M., Ferlay, J., Mathers, C., Forman, D., et al. (2012). Global burden of cancer in 2008: A systematic analysis of disability-adjusted life-years in 12 world regions. Lancet, 380, 1840-1850.
3. Allard, C. B., Dason, S., Lusis, J., & Kapoor, A. (2012). Prostate cancer screening: Attitudes and practices of family physicians in Ontario. Canadian Urological Association Journal, 6(3), 188-193.
4. Barry, M. J. (2009). Screening for prostate cancer-the controversy that refuses to die. New England Journal of Medicine, 360, 1351-1354.
5. Cooperberg, M. R., Carroll, P. R., & Klotz, L. (2011). Active surveillance for prostate cancer: Progress and promise. Journal of Clinical Oncology, 29, 3669-3676.
6. Chou, R., Croswell, J. M., Dana, T., Bougatsos, C., Blizina, I., Fu, R., et al. (2011). Screening for prostate cancer: A review of the evidence for the U.S. preventive services task force. Annals of Internal Medicine, 155, 762-771.
7. Lin, K., Croswell, J. M., Koenig, H., Lam, C., & Maltz, A. (2011) Prostate-specific antigen-based screening for prostate cancer: An evidence update for the U.S. preventive services task force. AHRQ publication no. 12-05160-EF-1, Oct 2011. Evidence synthesis number 90 (Screening for prostate cancer, topic page. U.S. Preventive Services Task Force. http://www.uspreventive servicestaskforce.org/uspstf/uspsprca.htm).
8. Albertsen, P. C. (2010). The unintended burden of increased prostate cancer detection associated with prostate cancer screening and diagnosis. Urology, 75, 399-405.
9. Litwin, M. S., Gore, J. L., Kwan, K., Brandeis, J. M., Lee, S. P., Withers, H. R., et al. (2007). Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer, 109, 2239-2247.
10. Talcott, J. A., Manola, J., Clark, J. A., Kaplan, I., Beard, C. J., Mitchell, S. P., et al. (2003). Time course and predictors of symptoms after primary prostate cancer therapy. Journal of Clinical Oncology, 21, 3979-3986.
11. Revicki, D. A., & Kaplan, R. M. (1993). Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life. Quality of Life Research, 2, 477-487.
12. Froberg, D. G., & Kane, R. L. (1989). Methodology for measuring health-state preferences-II: Scaling methods. Journal of Clinical Epidemiology, 42, 459-471.
13. Feeny, D., Furlong, W., Boyle, M., & Torrance, G. W. (1995). Multi-attribute health status classification systems: Health utilities index. PharmacoEconomics, 7, 490-502.
14. Euroqol Group. (1990). A new facility for the measurement of health related quality of life. Health Policy,16, 199-208.
15. Drummond, M. F., Sculpher, M. J., Torrance, G. W., O'Brien, B. J., & Stoddart, G. L. (2005). Chapter 6: Cost-utility analysis. In Methods for the economic evaluation of health care programmes. New York: Oxford University Press.
16. Heijnsdijk, E. A. M., Wever, E. M., Auvinen, A., Hugosson, J., Ciatto, S., Nelen, V., et al. (2012). Quality-of-life effects of prostate-specific antigen screening. New England Journal of Medicine, 367, 595-605.
17. Hayes, J. H., Ollendorf, D. A., Pearson, S. D., Barry, M. J., Kantoff, P. W., Stewart, S. T., et al. (2010). Active surveillance compared with initial treatment for men with low-risk prostate cancer. A decision analysis. The Journal of the American Medical Association, 304, 2373-2380.
18. Sox, H. (2012). Quality of life and guidelines for PSA screening (editorial). New England Journal of Medicine, 367(7), 669-671.
19. Krahn, M., Bremner, K. E., Tomlinson, G., Ritvo, P., Irvine, J., & Naglie, G. (2007). Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Quality of Life Research, 16, 509-522.
20. Krahn, M. D., Ritvo, P., Irvine, J., Tomlinson, G., Bremner, K. E., Bezjak, A., et al. (2003). Patient and community preferences for outcomes in prostate cancer: Implications for clinical policy. Medical Care, 41, 153-164.
21. Krahn, M. D., Bremner, K. E., Tomlinson, G., & Naglie, G. (2009). Utility and health-related quality of life in prostate cancer patients 12 months after radical prostatectomy or radiation therapy. Prostate Cancer and Prostatic Diseases,12, 361-368.
22. Saigal, C. S., Cornbein, J., Nease, R., & Litwin, M. S. (2001). Predictors of utilities for health states in early stage prostate cancer. Journal of Urology, 166, 942-946.
23. Stewart, S. T., Lenert, L., Bhatnagar, V., & Kaplan, R. (2005). Utilities for prostate cancer health states in men aged 60 and older. Medical Care, 43(4), 347-355.
24. Sommers, B. D., Beard, C. J., D'Amico, A. V., Kaplan, I., Richie, J. P., & Zeckhauser, R. J. (2008). Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer, 113, 2058-2067.
25. Meghani, S. H., Lee, C. S., Hanlon, A. L., & Bruner, D. W. (2009). Latent class analysis to understand heterogeneity in prostate cancer treatment utilities. BMC Medical Informatics and Decision Making, 9,47.
26. McTaggart-Cowan, H. (2011). Elicitation of informed general population health state utility values: A review of the literature. Value in Health,14, 1153-1157.
27. Shimizu, F., Fujino, K., Ito, Y. M., Fukuda, T., Kawachi, Y., Minowada, S., et al. (2008). Factors associated with variation in utility scores among patients with prostate cancer. Value in Health,11, 1190-1193.
28. Smith, D. S., Krygiel, J., Nease, R. F., Jr, Sumner, W. II, & Catalona, W. J. (2002). Patient preferences for outcomes associated with surgical management of prostate cancer. Journal of Urology,167, 2117-2122.
29. Jayadevappa, R., Schwartz, J. S., Chhatre, S., Wein, A. J., & Malkowicz, S. B. (2010). Association between utility and treatment among patients with prostate cancer. Quality of Life Research, 19, 711-720.
30. Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893-2917.
31. Hall, S., Schulze, K., Groome, P., McKillop, W., & Holowaty, E. (2006). Using cancer registry data for survival studies: The example of the Ontario cancer registry. Journal of Clinical Epidemiology, 59, 67-76.
32. Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40, 373-383.
33. Krahn, M., Ritvo, P., Irvine, J., Tomlinson, G., Bezjak, A., Trachtenberg, J., et al. (2000). Construction of the patient-oriented prostate utility scale (PORPUS): A multiattribute health state classification system for prostate cancer. Journal of Clinical Epidemiology, 53, 920-930.
34. Tomlinson, G., Bremner, K. E., Ritvo, P., Naglie, G., & Krahn, M. D. (2012). Development and validation of a utility weighting function for the Patient-Oriented Prostate Utility Scale (PORPUS). Medical Decision Making,32, 11-30.
35. Feeny, D., Furlong, W., Torrance, G. W., Goldsmith, C. H., Zhu, Z., DePauw, S., et al. (2002). Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care, 40, 113-128.
36. Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997). Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology, 50, 920-928.
37. Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., & Brook, R. H. (1998). The UCLA prostate cancer index: Development, reliability, and validity of a health-related quality of life measure. Medical Care, 36, 1002-1012.
38. Cabrol, M. P. R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria.
39. SAS Inc. SAS 9.1.3 for Windows. Cary, NC, USA.
40. Van Buuren, S., & Oudshoorn, CGM. (1999) Flexible multivariate imputation by MICE. Leiden: TNO preventie en Gezondheid, TNO/VGZ/PG 99054.
41. Crook, J., Borg, J., Evans, A., Toi, A., Saibishkumar, E. P., Fung, S., et al. (2011). 10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: Results for 1,100 patients. International Journal of Radiation Oncology Biology Physics, 80, 1323-1329.
42. Crook, J., Lukka, H., Klotz, L., Bestic, N., Johnston, M., & The Genitourinary Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. (2001). Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. Canadian Medical Association Journal, 164, 975-981.
43. Kopec, J. A., Williams, J. I., To, T., & Austin, P. C. (2000). Measuring population health: Correlates of the health utilities index among English and French Canadians. Canadian Journal of Public Health, 91, 465-470.
44. Maddigan, S. L., Feeny, D. H., & Johnson, J. A. (2005). Health related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Quality of Life Research, 14, 1311-1320.
45. Bremner, K. E., Chong, C. A. K. Y., Tomlinson, G., Alibhai, S. M. H., & Krahn, M. D. (2007). A review and meta-analysis of prostate cancer utilities. Medical Decision Making, 27, 288-298.
46. Statistics Canada. (2006) Census of population. Statistics Canada catalogue no. 97-560-XCB2006008 (Ontario, Code35) Date modified: 2011-04-07.
47. Statistics Canada. (2006). Catalogue number 97-563-XCB20060 05.2006 census.
48. Sterne, J. A., White, I. R., Carlin, J. B., Spratt, M., Royston, P., Kenward, M. G., et al. (2009). Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. British Medical Journal, 338, b2393. doi:10.1136/ bmj.b2393.
49. Willis, D. L., Gonzalgo, M. L., Brotzman, M., Feng, Z., Trock, B., & Su, L.-M. (2011). Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: A study of comparative effectiveness based upon validated quality of life outcomes. BJU International, 109, 898-905.
50. Wilson, T., & Torrey, R. (2011). Open versus robotic-assisted radical prostatectomy: Which is better? Current Opinion in Urology, 21, 200-205
51. Al-Mamgani, A., Heemsbergen, W. D., Peeters, S. T., & Lebesque, J. V. (2009). Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 73, 685-691.
52. Zelefsky, M. J., Levin, E. J., Hunt, M., Yamada, Y., Shippy, A. M., Jackson, A., et al. (2008). Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 70, 1124-1129.